Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 92.39B 84.15B 77.54B 70.53B 132B 8,555B 139B 944B 375B 4,673B 347B 339B 14,665B P/E 2026 *
15.5x
P/E 2027 * 14.8x
Enterprise Value 85.22B 77.62B 71.52B 65.06B 122B 7,892B 128B 870B 346B 4,310B 320B 313B 13,527B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 3.96x
Free-Float
72.51%
Yield 2026 *
0.41%
Yield 2027 * 0.44%
1 day-0.19%
1 week-3.64%
Current month-0.78%
1 month+14.28%
3 months+10.39%
6 months+43.28%
Current year+19.28%
1 week 916.66
Extreme 916.66
972.24
1 month 796.61
Extreme 796.61
991.73
Current year 591.52
Extreme 591.52
991.73
1 year 591.52
Extreme 591.52
991.73
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

SVP Controller

11,828 0.0117%
3/11/26 Exercice

Director

22,317 0.0221%
3/11/26 Don

Chief Technology Officer

-1,054 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-3.64%+21.80%+15.25% 92.39B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.28%-4.64%+24.69%+69.60% 416B
Weighted average by Cap. +0.29%-5.16%+25.93%+86.26%

Financials

2026 *2027 *
Net sales 18.81B 17.14B 15.79B 14.36B 26.95B 1,742B 28.32B 192B 76.38B 952B 70.59B 69.1B 2,987B 20.17B 18.37B 16.93B 15.4B 28.88B 1,867B 30.36B 206B 81.87B 1,020B 75.67B 74.07B 3,201B
Net income 6.43B 5.85B 5.39B 4.91B 9.2B 595B 9.67B 65.64B 26.09B 325B 24.11B 23.6B 1,020B 6.56B 5.97B 5.51B 5.01B 9.39B 607B 9.87B 67B 26.63B 332B 24.61B 24.09B 1,041B
Net Debt -7.17B -6.53B -6.02B -5.47B -10.27B -664B -10.79B -73.22B -29.1B -363B -26.89B -26.33B -1,138B -12.52B -11.4B -10.51B -9.56B -17.93B -1,159B -18.84B -128B -50.82B -633B -46.96B -45.97B -1,987B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
20/11/26 USD 920.69 -0.29% 878,261
19/11/26 USD 923.34 -2.35% 723,486
18/11/26 USD 945.53 -1.28% 705,406
17/11/26 USD 957.76 +0.56% 933,408
16/11/26 USD 952.40 -0.32% 700,861
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
920.69USD
Average target price
991.00USD
Spread / Average Target
+7.64%
  1. Stock Market
  2. Stocks
  3. REGN Stock